Finanziertes Projekt

Against skin cancer


Skin cancer is by far the most common type of cancer.

Finanziert dank:
  • Spender
  • Finanzierte Gesamtsumme
    • PromoFarma Kunden 1.800€
  • Direkte Empfänger 5

    Diejenigen Personen, die auf natürliche Art direkt von den im Projekt ausgeführten Aktionen begünstigt wurden.

  • Indirekte Empfänger 100

    Diejenigen identifizierbaren Personen, die einen potentiellen Effekt von den im Projekt durchgeführten Aktionen erfahren.

CRIS Cancer


  • Materialien 1.800€
  • Gesamt 1.800€


Globally, skin cancer is one of the most frequently detected cancers. The main types of skin cancer are: squamous cell carcinoma, basal cell carcinoma and melanoma. Melanoma is much less common than other types of cancer, but it is much more likely to invade nearby tissue and spread to other parts of the body.

The advanced and metastatic melanoma until a few years ago was practically a sentence, due to its poor prognosis and treatment difficulties. Thanks to research, in recent years, thanks to Immunotherapy, a hopeful way of treatment has been opened for these patients. Many patients with advanced disease have come to remit thanks to this type of therapy, even when there were no treatment options left. However, this field is still very new and is at a very early stage, and not all patients respond to these therapies.


  • Investigate the causes that cause some patients to respond and others not.
  • Investigate ways to detect which patients will or will not respond to immunotherapy.
  • Develop new immunotherapy treatments, more effective, more specialized and more directed to each patient.

Wer wird begünstigt?

Patients of the Immunooncology Unit of October 12 Hospital


Develop innovative therapies, new diagnostic and prognostic methods, to fight cancer of all patients.


CRIS Cancer erfüllt die 9 Prinzipien der Transparenz und guten Praktiken, die von der Lealtad Foundation analysiert werden, vollständig.

Fundacion Lealtad

Diese Seite verwendet Cookies. Wenn Sie weiter surfen, gehen wir davon aus, dass Sie die Verwendung akzeptieren. Mehr Information erhalten.